The offering will fund testing of a potential rival to Amgen’s Tezspire and is already the sixth for an immune drug developer this year, the most since 2021.

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

In a report released on October 7, Alexandre Raverdy from Kepler Capital maintained a Buy rating on Gestamp Automocion (0ROM – Research ...

Scholar Rock Holding Corp.’s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after ...

On CNBC's "Mad Money Lightning Round," Jim Cramer said FTAI Aviation is "too high" for him and prefers to be in RTX ...

Paid non-client promotion: Affiliate links for the products on this page are from partners that compensate us (see our advertiser disclosure with our list of partners for more details). However ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Chinese stocks were off to the races on Thursday after Chinese leaders gave investors what stimulus measures earlier in the week failed to do: indications that policymakers are finally alarmed ...

The stock market is racking up record highs again ... The Personal Consumption Expenditures price index, the Federal Reserve’s preferred inflation gauge, showed that the prices consumers ...

The Federal Reserve's preferred inflation measure on Friday provided the latest sign that price pressures are easing, a trend that is expected to fuel further Fed interest rate cuts this year and ...

Crude oil prices were trending down earlier today, extending a two-day losing streak as bearish news crowded out any bullish signals. Earlier in the week, news emerged that the rival governments ...